Abstract
Victoza (liraglutide) is a modern antidiabetic drug of GLP1 (glucagone like peptide) analogue group, since 2009 registered in Czech Republic. Victoza is used in therapy of type 2 diabetic patients with preserved endougenous insulin secretion, usually in combination with other peroral antidiabetic drugs or with basal insulin.
Victoza is applied once a day subcutaneously. The characteristical antidiabetic effect with ß cell protection is enhanced with supportive weigth reduction effect.
Positive cardiovascular influence is expected, however data from recent studies are not available at this time. In clinical practice, the mild upper dyspepsia after intiation of therapy is the most common side effect, usually subsiding in several days.
Alltogether, Victoza is a well tolerated antidiabetic medication decreasing glycated hemoglobin up to 15 mmol/l with minimal risk of hypoglycaemia.